Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac<sup>®</sup>) in chronic immune thrombocytopenic purpura
Louis M. Aledort(Icahn School of Medicine at Mount Sinai), O. Zenker(CSL (Switzerland)), Benjamin Brenner(Rambam Health Care Campus), Tadeusz Robak(Medical University of Lodz), A. Salama(Charité - Universitätsmedizin Berlin), Adrian C. Newland(Queen Mary University of London), Л. В. Ковалева(Russian Academy of Sciences), Diane J. Nugent(Children's Hospital of Orange County)
Cited by 12
Related Papers
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907